Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders

Author： Hoppensteadt Debra A   Kaiser Brigitte   Fareed Jawed  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.10, Iss.11, 2001-11, pp. : 1925-1935

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tissue factor pathway inhibitor for cardiovascular disorders

By Kaiser B.   Hoppensteadt D.A.   Fareed J.  

Expert Opinion on Emerging Drugs, Vol. 5, Iss. 1, 2000-02 ,pp. : 73-87

Informa Healthcare

Access to resources Recommend Favorite

Recombinant TFPI and variants:potential implications in the treatment of cardiovascular disorders

By Kaiser B.   Hoppensteadt D.H.   Fareed J.  

Expert Opinion on Investigational Drugs, Vol. 7, Iss. 7, 1998-07 ,pp. : 1121-1139

Informa Healthcare

Access to resources Recommend Favorite

Gene Therapy with Transcription Factor Decoy Oligonucleotides as a Potential Treatment for Cardiovascular Diseases

By  

Current Drug Targets, Vol. 4, Iss. 4, 2003-05 ,pp. : 339-346

Bentham Science Publishers

Access to resources Recommend Favorite

Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment

By  

Current Pharmaceutical Design, Vol. 19, Iss. 9, 2013-03 ,pp. : 1710-1719

Bentham Science Publishers

Access to resources Recommend Favorite

Immediate Effects of Fluvastain on Circulating Soluble Endothelial Protein C and Free Tissue Factor Pathway Inhibitor in Acute Coronary Syndromes

By Atalar Enver   Coskun Secuk   Haznedaroglu Ibrahim   Yücel Neslihan   Ozer Necla   Sivri Bulent   Aksoyek Serdar   Ovunc Kenan   Ozmen Ferhan  

Cardiovascular Drugs and Therapy, Vol. 19, Iss. 3, 2005-05 ,pp. : 177-181

Springer Publishing Company

Access to resources Recommend Favorite